Company intelligence / Profile preview

ANTUREC Pharmaceuticals GmbH

Frankfurt am Main, Hessen, Germanyanturec.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Currently conducting a Phase III open-label, controlled clinical trial for patients with unresectable or metastatic soft-tissue sarcoma, evaluating whether tTF-NGR in combination with standard trabectedin chemotherapy prolongs progression-free survival compared to trabectedin alone[2]. The first patient for the Phase III study was enrolled on November 12, 2021[6].

Therapeutic areas: Oncology
Modalities: Fusion proteinsrecombinant proteins
Industry: Biotech

Drug pipeline

1 asset

tTF-NGR

Partnerships

Universität Stuttgart[2]

Beyond the preview

Go deeper on ANTUREC Pharmaceuticals GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANTUREC Pharmaceuticals GmbH.

Explore the full profile